Our lab is dedicated to transforming cellular immunotherapy by developing advanced CAR T cell therapies that overcome cancer resistance. Drawing on our strong foundation in using high throughput CRISPR screens to functionally characterize tumor antigen variants, we are engineering resilient CAR T cells with refined gene editing. Recently, we have expanded our focus to include generative AI for designing de novo protein binders—innovative CAR binding domains that target resistant tumor antigens. Our emerging work drives a deeper understanding of cancer cell resistance and is poised to pave the way for more tailored and effective immunotherapeutic strategies.